JCO:老年乳腺癌患者肿瘤治疗相关的认知功能结局

2018-10-31 MedSci MedSci原创

JCO近期发表了一篇文章,研究治疗及年龄相关因素对老年乳腺癌患者认知功能的影响。

JCO近期发表了一篇文章,研究治疗及年龄相关因素对老年乳腺癌患者认知功能的影响。

在2010年8月至2015年12月期间,研究纳入新诊断的非转移性乳腺癌患者(n = 344)和无癌症的对照研究对象(n = 347),入组标准年龄为60岁及以上,无痴呆或神经系统疾病。通过调查,癌症治疗认知功能自我评估,以及针对注意力,处理速度和执行功能(APE)和学习记忆(LM)的神经心理学测试分析认知功能。研究结果表明,肿瘤组和对照组研究对象年龄在60至98岁之间,受过良好教育,并具有相似的基线认知得分。治疗与认知评分有关,接受化疗的肿瘤患者APE评分较差,且在12个月时开始激素治疗的患者LM评分比其他组低。年龄增加与认知基线评分降低相关,情感脆弱与基线APE和自我报告功能下降相关。

文章最后认为,乳腺癌系统治疗和衰老与老年乳腺癌患者的认知功能评分降低相关。这些研究结果有助于患者的治疗及护理决策。

原始出处:

Jeanne S. Mandelblatt, Brent J. Small, et al. Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer Study. JCO. October 2018 doi: 10.1200/JCO.18.00140

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1891558, encodeId=9a231891558d9, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Nov 18 01:11:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301073, encodeId=ca0513010e399, content=<a href='/topic/show?id=10333293491' target=_blank style='color:#2F92EE;'>#功能结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32934, encryptionId=10333293491, topicName=功能结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d275294, createdName=andy2087, createdTime=Fri Nov 02 02:11:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304102, encodeId=093e13041026f, content=<a href='/topic/show?id=c5558298426' target=_blank style='color:#2F92EE;'>#肿瘤治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82984, encryptionId=c5558298426, topicName=肿瘤治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Nov 02 02:11:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571143, encodeId=fa5515e114339, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Nov 02 02:11:00 CST 2018, time=2018-11-02, status=1, ipAttribution=)]
    2018-11-18 lidong40
  2. [GetPortalCommentsPageByObjectIdResponse(id=1891558, encodeId=9a231891558d9, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Nov 18 01:11:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301073, encodeId=ca0513010e399, content=<a href='/topic/show?id=10333293491' target=_blank style='color:#2F92EE;'>#功能结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32934, encryptionId=10333293491, topicName=功能结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d275294, createdName=andy2087, createdTime=Fri Nov 02 02:11:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304102, encodeId=093e13041026f, content=<a href='/topic/show?id=c5558298426' target=_blank style='color:#2F92EE;'>#肿瘤治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82984, encryptionId=c5558298426, topicName=肿瘤治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Nov 02 02:11:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571143, encodeId=fa5515e114339, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Nov 02 02:11:00 CST 2018, time=2018-11-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1891558, encodeId=9a231891558d9, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Nov 18 01:11:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301073, encodeId=ca0513010e399, content=<a href='/topic/show?id=10333293491' target=_blank style='color:#2F92EE;'>#功能结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32934, encryptionId=10333293491, topicName=功能结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d275294, createdName=andy2087, createdTime=Fri Nov 02 02:11:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304102, encodeId=093e13041026f, content=<a href='/topic/show?id=c5558298426' target=_blank style='color:#2F92EE;'>#肿瘤治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82984, encryptionId=c5558298426, topicName=肿瘤治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Nov 02 02:11:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571143, encodeId=fa5515e114339, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Nov 02 02:11:00 CST 2018, time=2018-11-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1891558, encodeId=9a231891558d9, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Nov 18 01:11:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301073, encodeId=ca0513010e399, content=<a href='/topic/show?id=10333293491' target=_blank style='color:#2F92EE;'>#功能结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32934, encryptionId=10333293491, topicName=功能结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d275294, createdName=andy2087, createdTime=Fri Nov 02 02:11:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304102, encodeId=093e13041026f, content=<a href='/topic/show?id=c5558298426' target=_blank style='color:#2F92EE;'>#肿瘤治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82984, encryptionId=c5558298426, topicName=肿瘤治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Nov 02 02:11:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571143, encodeId=fa5515e114339, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Nov 02 02:11:00 CST 2018, time=2018-11-02, status=1, ipAttribution=)]

相关资讯

病例分享|首诊IV期伴内脏转移HER2阳性晚期乳腺癌一例

本病例报道了一例经外院手术的HER2阳性IV期乳腺癌患者。一线曲妥珠单抗联合多西他赛及卡铂(TCH)化疗后,肝脏病灶消失,骨破坏明显改善,疗效评价为PR。后续给予了持续性抗HER2治疗联合单药多西他赛维持治疗,PFS达49月。虽然手术治疗作为该患者初始治疗是不合适的,但是该患者在后续的抗HER2治疗及化疗中明显获益,弥补了初始治疗的不足。在六周期HER2靶向治疗及化疗达到PR后,考虑患者体力状况及

Nat Commun:怀孕周期与乳腺癌风险

最近一项新研究显示,女性的身体在一个特定的怀孕周期会经历“显著”变化,这种变化会明显降低她们在日后患乳腺癌的风险。此前有研究发现如果女性在30岁之前生育可以降低患乳腺癌的风险。最新的这项由丹麦和挪威的科学家合作完成的新研究声称,他们已确定这些变化具体发生在哪个孕周。该研究成果已发表在10月23日的《Nature Communications》上。

金锋教授、胡夕春教授解析如何全方位探讨乳腺癌内分泌治疗策略

第十三届上海国际乳腺癌论坛(SIBCS)顺利召开。内分泌治疗作为乳腺癌的一大治疗策略,在本届SIBCS上也是众多医学同道中的热议话题。有幸邀请中国医科大学附属第一医院的金锋教授和复旦大学附属肿瘤医院的胡夕春教授共同对话,一起聊聊关于乳腺癌内分泌治疗的思考与体会。

粉红十月,全面推进乳腺癌“个体化”治疗是关键

每年10月是乳腺癌防治月,又称“粉红丝带月”。为进一步提升公众对女性健康的关注,呼吁乳腺癌早诊早治,坚定患者治愈信心,上海罗氏制药有限公司支持的全国乳腺癌治愈百家谈媒体系列活动于近日在沪启动。该项目计划在未来一年时间内,邀请全国上百位专家学者,临床医生、护士,患者等共话乳腺癌防治,并通过主流媒体的持续性传播,聚焦精准医疗时代下,以患者为中心的乳腺癌的规范化和个体化治疗。同期,由中国抗癌协会乳腺

2018 SIBCS:程蕾蕾教授:乳腺癌血脂异常的全程管理建议

随着医学研究的不断进步,化疗、靶向、免疫治疗等药物层出不穷,有效改善了乳腺癌患者的预后,也使得乳腺癌的诊疗变得越来越精准化。在更多关注治疗疗效的同时,研究者也越来越关注乳腺癌患者的生活质量,尤其是对心血管事件等并发症尤为关注。在第十三届上海国际乳腺癌论坛期间,【有幸邀请到程蕾蕾教授就乳腺癌血脂异常的流行病学现状以及全程管理建议等作一专访。

粉红十月,全国乳腺癌治愈百家谈媒体系列活动在沪正式启动

每年10月是乳腺癌防治月,又称“粉红丝带月”。为进一步提升公众对女性健康的关注,呼吁乳腺癌早诊早治,坚定患者治愈信心,上海罗氏制药有限公司支持的全国乳腺癌治愈百家谈媒体系列活动于近日在沪启动。该项目计划在未来一年时间内,邀请全国上百位专家学者,临床医生、护士,患者等共话乳腺癌防治,并通过主流媒体的持续性传播,聚焦精准医疗时代下,以患者为中心的乳腺癌的规范化和个体化治疗。以患者为中心,全面推进乳